← Back to Search

Continuous Glucose Monitoring for Gestational Diabetes (CAPO Trial)

N/A
Recruiting
Led By Audrey Merriam, MD, MS
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Women between 18-50 years old
Be between 18 and 65 years old
Must not have
Fetal growth restriction diagnosed during the current pregnancy
Abnormal diagnostic genetic testing or genetic screening for the fetus in the current pregnancy prior to randomization
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment, through delivery by 40 weeks gestation and the immediate postpartum hospitalization up to 7 days postpartum
Awards & highlights
No Placebo-Only Group

Summary

This trial will use continuous glucose monitoring to see if it lowers the rate of serious complications in women with A2 gestational diabetes.

Who is the study for?
This trial is for pregnant women aged 18-50 with a single baby and diagnosed with A2 gestational diabetes needing medication, between 24-36 weeks of pregnancy. It's not for those with pregestational diabetes, multiple babies, fetal growth issues, or certain medical conditions like lupus or chronic hypertension.
What is being tested?
The study compares the effects of continuous glucose monitoring versus routine fingerstick blood checks four times daily in managing A2 gestational diabetes during pregnancy. The goal is to see if constant monitoring can reduce complications such as high birth weight and neonatal hypoglycemia.
What are the potential side effects?
While the trial itself does not list specific side effects, continuous glucose monitoring generally has minimal risks which may include skin irritation from the sensor adhesive or discomfort at the sensor site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman aged between 18 and 50.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My current pregnancy has been diagnosed with fetal growth restriction.
Select...
My current pregnancy has shown abnormal genetic test results for the fetus.
Select...
I have been diagnosed with too much amniotic fluid.
Select...
I have a health condition such as lupus, high blood pressure, cancer, or heart disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment, through delivery by 40 weeks gestation and the immediate postpartum hospitalization up to 7 days postpartum
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment, through delivery by 40 weeks gestation and the immediate postpartum hospitalization up to 7 days postpartum for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Composite
Secondary study objectives
cesarean delivery for an arrest of labor disorder
hypertensive disorders of pregnancy.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Continuous Glucose MonitorExperimental Treatment1 Intervention
Monitoring of control of gestational diabetes with use of a continuous glucose monitor
Group II: Routine CareActive Control1 Intervention
Monitoring of control of gestational diabetes with routine care and use of a glucometer and fingersticks 4 times a day
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Continuous Glucose Monitor
2021
Completed Early Phase 1
~860

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,920 Previous Clinical Trials
3,031,550 Total Patients Enrolled
Audrey Merriam, MD, MSPrincipal InvestigatorAssistant Professor; Assistant Professor, Department of Obstetrics, Gynecology and Reproductive Sciences
1 Previous Clinical Trials
93 Total Patients Enrolled

Media Library

Continuous Glucose Monitor Clinical Trial Eligibility Overview. Trial Name: NCT04219085 — N/A
Gestational Diabetes Research Study Groups: Continuous Glucose Monitor, Routine Care
Gestational Diabetes Clinical Trial 2023: Continuous Glucose Monitor Highlights & Side Effects. Trial Name: NCT04219085 — N/A
Continuous Glucose Monitor 2023 Treatment Timeline for Medical Study. Trial Name: NCT04219085 — N/A
~17 spots leftby Dec 2025